🇺🇸 FDA
Patent

US 7446108

Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists

granted A61PA61P1/00A61P1/04

Quick answer

US patent 7446108 (Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists) held by Neurocrine, Inc. expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Neurocrine, Inc.
Grant date
Tue Nov 04 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61P, A61P1/00, A61P1/04, A61P25/00, A61P25/20